CHIT CHIT1 is is a a no novel the therapeutic tar arget in in - - PowerPoint PPT Presentation

CHIT CHIT1 is is a a no novel the therapeutic tar arget in in IPF: an anti-fibrotic effi ficacy of

• f OATD

TD-01, , a a pot potent and and sel elective chit chitinase inh inhibitor, in n the the mou

• use

se mod

• del of
• f pulm

pulmonary ry fibrosis

Barbara Dymek

• P. Sklepkiewicz, M. Mlacki, A. Zagozdzon, R. Koralewski, M. Mazur, M.Paplinska-Goryca, P. Nejman-Gryz,
• M. Proboszcz, K. Gorska, M. Maskey-Warzechowska, N. Przysucha, R. Krenke, A. Golebiowski, P. Dobrzanski, K. Dzwonek

Conflict of interest disclosure

❑ I have no real or perceived conflicts of interest that relate to this presentation. ❑ I have the following real or perceived conflicts of interest that relate to this presentation:

Affiliation / Financial interest Commercial Company Grants/research support: Honoraria or consultation fees: Participation in a company sponsored bureau: Stock shareholder: Spouse / partner: Other support / potential conflict of interest:

This event is accredited for CME credits by EBAP and EACCME and speakers are required to disclose their potential conflict of interest. The intent of this disclosure is not to prevent a speaker with a conflict of interest (any significant financial relationship a speaker has with manufacturers or providers of any commercial products or services relevant to the talk) from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for audience members to determine whether the speaker’s interests, or relationships may influence the presentation. The ERS does not view the existence of these interests or commitments as necessarily implying bias or decreasing the value of the speaker’s presentation. Drug or device advertisement is forbidden.

X

CHIT1 – structure and function

ERS 2018

Ch Chitot

• tri

riosi sidase se (CH CHIT1) is a member of the GH18 family of chitinases which consists of enzymatically active hydrolases, CHIT1 and AMCase, and enzymatically non-active chitinase-like proteins (YKL-40, YKL-39,

• viductin).

Evolutionary CHIT1 confers protection against chitin-containing

• pathogens. However, in humans, it has been implicated in pathology
• f multiple inflammatory and fibrotic diseases (IPF, sarcoidosis, COPD)

where it is highly induced and associated with disease progression. The exact mode of action of CHIT1 remains to be elucidated.

Faras F, 2015

CHIT1 pr prot

• tei

ein st stru ructure

Targeting CHIT1 in interstitial lung diseases: rationale

Hum uman:

• CHIT1 gene expression is significantly upregulated in lungs of IPF

patients as compared to healthy subjects. Data extracted from the study GSE32537 (IPF n=119; Control n=50). (Yang IV, 2013)

• CHIT1 activity is elevated in BAL and serum of patients with

interstitial lung diseases e.g. IPF, systemic sclerosis-associated lung fibrosis and sarcoidosis. (Bargagli E, 2007, Lee CG, 2012)

• CHIT1 activity in serum of sarcoidosis patients correlates with a

disease stage and clinical prognosis and is considered the best biomarker of disease progression. (Boot R, 2010)

ERS 2018

Mouse:

• Lung fibrosis induced by bleomycin is enhanced in transgenic mice over-expressing CHIT1 and is reduced in CHIT1

knockout mice. (Lee CG, 2012)

CHIT1 activity is elevated in ILDs (IPF and sarcoidosis)

In collaboration with Medical University of Warsaw

The analysis of chitinolytic activity in samples collected from patients demonstrate si sign gnificantly increa eased ed chitinol

• lyt

ytic act ctivi vity in in seru rum and nd in in indu nduced sput putum in patients with IPF and sarcoidosis when compared to normal controls. These results are in accordance with the published data.

ERS 2018

Ser erum Ind nduced ed spu putu tum BAL fluid id

CHIT1 is expressed in macrophages and lymphocytes in BALf from IPF patients

Bio - San Diego 6

In collaboration with Medical University of Warsaw

77% of all BALf cells in IPF (n=8) express CHIT1. Cytological analysis demonstrated that macrop

• phages (83% positive) and

lymphocyt ytes es (51%) are the main cell subtypes expressing CHIT1.

ERS 2018

BAL fluid id cell ells smea ears – anti ti-CHIT1 IHC

OATD-01: the first chitinase inhibitor in clinical development

• OATD-01 is a highly potent, dual AMCase and CHIT1 small-molecule inhibitor with a nanomolar activity.
• OATD-01 demonstrated a strong anti-inflammator
• ry and anti-remod
• del

eling activi vity in animal models of airway inflammation induced by house dust mite (HDM)

• OATD-01 completed

ed Pha hase se Ia Ia clinical studies (single ascending dose in healthy volunteers)

• No serious adverse effects and no withdrawals due to AEs reported
• Favorable PK profile, appropriate for oral, once-a-day dosing
• Results presented at ERS congress (late-breaking abstract "Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor

for the treatment of respiratory diseases", Sep 19th, 8:30)

• Enrolment for Phase Ib MAD study to start in Q4 2018

hA hAMCase se hC hCHIT1 mAMCa Case se mCH CHIT1 OATD-01 IC50 [nM] 9,2 23,4 7,8 27,5

ERS 2018

OATD-01: mouse PK profile

OATD-01 Pharmacokinetic Parameters Route IV PO Dose (mg/kg) 3 10 C0 or Cmax(mg/L) 3,97 3,42 Tmax(h) n/a 2,0 CL (mL/min/kg) 5,8 n/a Vss (L/kg) 1,01 n/a T½ (h) 2,09 1,88 Bioavailability (F%) n/a 77%

OATD-01 has a favorable pharmacokinetic profile in mice suitable for once- or twice-a-day oral dosing regimen in mice

ERS 2018

CHIT1 in upregulated in lung fibrosis mouse model

CHIT1 is upregulated in the lungs in the belomycin-induced pulmonary fibrosis model and localizes to fibrotic lesions.

ERS 2018

C57Bl/6

Control d3 d7 d14 d21 CHIT1 PSR

PK/PD study of OATD-01 in lung fibrosis model

OATD-01 administered once or twice a day led to a siginificant inhibition of chitinolytic activity (PD marker) in lung homogenates for 24h confirming the extended pharmacodynamic activity in lungs

ERS 2018

OATD-01 efficacy in lung fibrosis model: comparison with pirfenidone

• 21-day-long mouse model of pulmonary fibrosis induced by triple intranasal administrations of bleomycin
• Therapeutic scheme of treatment: oral bid administration of OATD-01 and pirfenidone starting at day 7
• Lung fibrosis assessed at day 21

C57Bl/6

ERS 2018 ERS 2018

OATD-01 efficacy in lung fibrosis model: comparison with pirfenidone

Control Bleomycin OATD-01 Pirfenidone

OATD-01 exhibited significant anti-fibrotic activity, comparable to pirfenidone, as assessed by the modified Ashcroft scale

ERS 2018

The significant reduction in Ashcroft score and in lung weight following OATD-01 administration was associated with suppression of the bleomycin-induced chitinolytic activity in plasma (4h after last dose) confirming target engagement.

OATD-01 efficacy in lung fibrosis model: comparison with pirfenidone

ERS 2018

OATD-01 efficacy in lung fibrosis model: comparison with nintedanib

• 21-day-long mouse model of pulmonary fibrosis induced by a single intratracheal administrations of bleomycin
• Therapeutic scheme of treatment starting at day 7; oral administration of OATD-01 and nintedanib once-a-day
• Lung fibrosis assessed at day 21
• Independent study – performed at CRO

C57Bl/6

ERS 2018

15

OATD-01 dosed orally at 100 mg/kg qd demonstrated strong antifibrotic efficacy comparable to nintedanib Significant, dose-dependent inhibition of chitinolytic activity in plasma was observed 24h after the last dose of OATD-01 confirming its extended PD activity.

OATD-01 efficacy in lung fibrosis model: comparison with nintedanib

ERS 2018

Summary

➢ CHIT1 activity is is el elev evated in in ser serum um an and ind nduc uced ed sp sput utum um of

• f IPF

PF pa patien ents an and it it is is a poten ential al novel ther erap apeut eutic target et in in IPF ➢ OATD TD-01 01 is is a po poten ent, sel elec ective, e, or

• ral

ally ac active sm smal all-mol

• lec

ecul ule inhi hibi bitor

• r of
• f chi

hitina nases es tha hat is is cur urren ently in in the he phase ase I clini nical al trial als ➢ OATD TD-01 01 de demon

• nstrated

ed str trong

• ng ther

herap apeut utic effic ficac acy, com

• mpar

arabl ble to to pi pirfeni enido done an and ni nintedan anib, in in the he bleo eomycin-ind nduced ed mous use mode del of

• f pulmon
• nary fibrosi

sis

ERS 2018

Acknowledgements

SMC C Labor

• rator
• ries,

es, Japa pan

Depart rtment of

• f Med

edic icinal Ch Chem emis istry ry Adam Golebiowski Robert Koralewski Marzena Mazur Michal Kowalski Depart rtment of

• f Bi

Biolo logy Karolina Dzwonek Pawel Dobrzanski Piotr Sklepkiewicz Michal Mlacki Agnieszka Zagozdzon Aleksandra Rymaszewska Anna Siwinska Depart rtment of

• f Develop
• pment

Stanislaw Pikul Joanna Lipner

Depart rtment of Intern ernal Med edicine, Pul Pulmon

• nary

ry Disea seases es and nd Aller ergy gy, Med edical Uni niver ersi sity of Warsaw

• Prof. Rafal Krenke

Magdalena Paplinska-Goryca Patrycja Nejman-Gryz Malgorzata Proboszcz Katarzyna Gorska Marta Maskey-Warzechowska Natalia Przysucha

FINANCIAL SUPPORT

„Preclinical research and clinical trials of a first-in-class development candidate in therapy of asthma and inflammatory bowel disease” ERS 2018